Melatonin: an anti-tumor agent for osteosarcoma
Open Access
- 29 November 2019
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-8
Abstract
Osteosarcoma is the most common bone tumors which consisted of malignant mesenchymal cells generating osteoid and immature bone. It has been showed that osteosarcoma is common in children and adolescents and shows high mortality rate. A variety of therapeutic approaches (i.e., resection surgery, combined with chemotherapy and radiotherapy) have been used as conventional treatments in patients with osteosarcoma. Despite several attempts to improve therapeutic response, the rate of survival for osteosarcoma has not changed during the past 3 decades. Therefore, the discovery and developing new effective therapeutic platforms are required. Along to the established anti-cancer agents, some physiological regulators such melatonin, have been emerged as new anti-cancer agents. Melatonin is an indolamine hormone which is secreted from the pineal glands during the night and acts as physiological regulator. Given that melatonin shows a wide spectrum anti-tumor impacts. Besides different biologic activities of melatonin (e.g., immunomodulation and antioxidant properties), melatonin has a crucial role in the formation of bones, and its deficiency could be directly related to bone cancers. Several in vitro and in vivo experiments evaluated the effects of melatonin on osteosarcoma and other types of bone cancer. Taken together, the results of these studies indicated that melatonin could be introduced as new therapeutic candidate or as adjuvant in combination with other anti-tumor agents in the treatment of osteosarcoma. Herein, we summarized the anti-tumor effects of melatonin for osteosarcoma cancer as well as its mechanism of action.Keywords
This publication has 74 references indexed in Scilit:
- Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatoninBritish Journal of Cancer, 2012
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcomaCancer, 2011
- Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathwayBreast Cancer Research, 2010
- Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP modelJournal of Pineal Research, 2010
- IKKγ protein is a target of BAG3 regulatory activity in human tumor growthProceedings of the National Academy of Sciences, 2010
- Scientific Basis for the Potential Use of Melatonin in Bone Diseases: Osteoporosis and Adolescent Idiopathic ScoliosisJournal of Osteoporosis, 2010
- Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in OsteosarcomasThe American Journal of Pathology, 2009
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInternational Journal of Cancer, 2009
- Stature of young people with malignant bone tumorsPediatric Blood & Cancer, 2003
- IntegrinsCell, 2002